Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Ipsen

Appointments: Celgene's COO Departs, New CEOs At Abeona, Kleo and Corvidia And Board Changes

This week's company moves include the sudden departure of Celgene's COO, new CEOs at Abeona Therapeutics, Kleo Pharmaceuticals and Corvidia Therapeutics, while board appointments have been made at Neurocentrx, Hemogenyx Pharmaceuticals, Emergex Vaccines and Rezolute Inc.

Appointments BioPharmaceutical

Ipsen Dreams Of Capital Position In Oncology

Ipsen's chief medical officer Sotirios Stergiopoulos talks about the company's R&D and licensing strategy that he hopes will push Ipsen's oncology unit to the next level.  

Commercial Cancer

Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.

Drug Review Approvals

CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC

The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.

Policy & Regulation Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Beaufour Ipsen
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • David Meek, CEO
    Claude Bertrand, PhD, EVP, R&D & CSO
    Aymeric Le Chatelier, EVP, Fin.
    Ivana Magovcevic-Liebisch, EVP, CBO
    Benoit Hennion, EVP, Pres., Primary Care
  • Contact Info
  • Ipsen
    Phone: (33) 1 58 33 50 00
    65 quai George Gorse
    Boulogne-Billancourt, 92100
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register